全球吸入麻醉市场按产品、最终用户、应用、地区、范围和预测划分

吸入麻醉的市场规模及预测

2024 年吸入麻醉市场规模价值为 18.2 亿美元，预计到 2031 年将达到 27 亿美元，2024 年至 2031 年的复合年增长率为 5.61%。在全球范围内，吸入麻醉是指透过吸入输送麻醉药物的方法，在手术过程中促使可逆性的意识和感觉丧失。它广泛用于手术中维持镇静，特别是对于需要长时间麻醉或精确麻醉管理的患者。最常用的药物是七氟醚、异氟醚和地氟醚，透过面罩和机械呼吸器给药。吸入麻醉通常应用于各种医学专业的医院和门诊手术中心，包括一般外科、骨科和儿科。

输送系统的进步和更安全、更有效的麻醉药物的开发使得这项技术的未来充满希望，推动其在医疗保健领域的持续应用。

吸入麻醉市场定义/概述

吸入麻醉是使用吸入麻醉药物使您在医疗过程中失去意识并减轻疼痛。这些药物通常使用面罩或呼吸管吸入并直接注射到患者的肺部。

此外，吸入麻醉广泛应用于各种外科手术，包括一般外科手术、骨科手术、妇科手术和牙科手术。其用途包括住院和门诊护理，为各个年龄层的患者提供安全有效的镇静。

全球吸入麻醉市场动态

主要市场驱动因子

手术数量增加

由于全球人口老化和慢性病的增加，外科手术的数量正在增加。根据世界卫生组织 (WHO) 的数据，每年进行超过 3.1 亿例大型外科手术，推动了世界各地手术室对吸入麻醉的需求。

麻醉学的进展

七氟醚和地氟醚等更安全、更有效的吸入麻醉药物的开发提高了麻醉的安全性。这些药物可减少恢復时间和术后併发症，因此成为首选药物。预计到 2027 年，全球对七氟醚的需求将以 4% 的复合年增长率成长。

门诊手术增加

借助微创技术进行门诊和当日手术的趋势日益增长，推动了对短效麻醉解决方案的需求。在美国，到 2023 年，门诊手术将占所有外科手术的 60% 以上，这将促使吸入麻醉剂的需求激增。

增加对医疗基础设施的投资

新兴市场，尤其是亚太地区的新兴市场，正大力投资医疗保健基础设施。预计到 2023 年，光是中国就在医疗保健领域投资超过 700 亿美元，这将推动对最新麻醉设备和解决方案（例如吸入麻醉）的需求。

主要问题

吸入麻醉剂成本高

七氟醚和地氟醚等现代麻醉剂的成本过高，尤其是对于中低收入国家的医护人员而言，限制了它们的使用。

环境问题

众所周知，吸入麻醉剂具有较高的全球暖化潜势 (GWP)，并会促使气候变迁。人们越来越担心这些药物对环境的影响，促使医疗保健产业探索更永续的替代品。

术后併发症的风险

虽然现代药物通常是安全的，但有些患者会出现术后副作用，如噁心、呕吐和呼吸问题。这可能会使医疗保健提供者犹豫是否使用吸入麻醉剂。

严格的监理要求

新型麻醉药物的开发和批准在各国都面临严格的监管，这减缓了市场成长并增加了将新产品推向市场的成本和时间。

主要趋势：

转向短效麻醉剂

人们越来越倾向于使用七氟醚和地氟醚等短效吸入麻醉剂，因为它们可以缩短恢復时间、减少术后併发症、提高患者吞吐量和手术效率。

配送系统的技术进步

麻醉输送系统的创新，包括先进的蒸发器技术和自动化麻醉工作站，提高了吸入麻醉的精确度和安全性，从而实现了更有效、更可控的给药。

门诊量和门诊手术量增加

门诊和门诊手术日益增长的趋势推动了对促进快速恢復和最小副作用的吸入麻醉剂的需求，从而支持了当日手术数量的增加。

环保麻醉剂的出现

人们的注意力一直集中在开发具有低全球暖化潜势 (GWP) 和对环境影响最小的环保吸入麻醉剂。

目录

第 1 章全球吸入麻醉市场简介

• 市场介绍
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 主要来源
• 资料来源列表

第 4 章全球吸入麻醉市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析

第5章全球吸入麻醉市场（依产品）

• 概述
• 地氟烷
• 异氟烷
• 七氟醚

第6章 全球吸入麻醉市场（依应用）

• 概述
• 维护
• 简介

第7章 全球吸入麻醉市场（按最终用户）

• 概述
• 医院
• 门诊手术中心

第8章 全球吸入麻醉市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第 9 章全球吸入麻醉市场的竞争格局

• 概述
• 各公司的市场排名
• 主要发展策略

第10章 公司简介

• AbbVie Inc.
• Baxter International Inc.
• Dechra Pharmaceuticals PLC
• Fresenius Kabi AG
• Hikma Pharmaceuticals PLC
• Jiangsu Hengrui Medicine Co. Ltd
• Lunan Pharmaceutical Group Co. Ltd
• Merck KGaA
• Piramal Enterprises Limited
• Troikaa Pharmaceuticals Ltd

第 11 章 重大进展

• 产品发布/开发
• 合併和收购
• 业务扩展
• 伙伴关係和合作关係

第 12 章附录

• 相关研究

Inhalation Anesthesia Market Size And Forecast

Inhalation Anesthesia Market size was valued at USD 1.82 Billion in 2024 and is projected to reach USD 2.7 Billion by 2031 , growing at a CAGR of 5.61% from 2024 to 2031 . Global inhalation anesthesia refers to a method of delivering anesthetic agents through inhalation, inducing a reversible loss of consciousness and sensation during surgical procedures. It is widely used in surgeries to maintain sedation, particularly for patients requiring long-term or precise anesthesia control. The primary agents used include sevoflurane, isoflurane, and desflurane, administered via masks or ventilators. Inhalation anesthesia is commonly applied in hospitals and ambulatory surgical centers across various medical fields, including general surgery, orthopedics, and pediatrics.

The future of this technique looks promising, with advancements in delivery systems and the development of safer, more efficient anesthetic agents driving its continued adoption in healthcare.

Inhalation Anesthesia Market: Definition/ Overview

Inhalation anesthesia is the use of anesthetic drugs through inhalation to induce unconsciousness and pain reduction during medical procedures. These drugs are usually inhaled using a mask or breathing tube and administered directly to the patient's lungs, where they are absorbed into the bloodstream and transported to the brain, causing loss of consciousness and pain.

Furthermore, inhalation anesthesia is widely utilized in a variety of surgical procedures, including general surgeries, orthopedic surgeries, gynecological treatments, and dental surgeries. Its applications include both inpatient and outpatient settings, providing safe and effective sedation to patients of all ages.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Inhalation Anesthesia Market Dynamics

The key market dynamics that are shaping the global inhalation anesthesia market include:

Key Market Drivers:

Rising Number of Surgical Procedures

: With an aging global population and increasing prevalence of chronic diseases, the number of surgeries is rising. According to the World Health Organization (WHO), over 310 million major surgeries are performed annually, driving the demand for inhalation anesthesia in operating rooms worldwide.

Advancements in Anesthetic Agents

: The development of safer and more efficient inhalation anesthetic agents, such as sevoflurane and desflurane, has enhanced the safety profile of anesthesia. These agents reduce recovery times and post-operative complications, making them preferred choices. The global demand for sevoflurane is expected to grow at a compound annual growth rate (CAGR) of 4% through 2027.

Increasing in Outpatient Surgeries

: The growing trend toward outpatient or same-day surgeries, supported by minimally invasive techniques, is driving demand for short-acting anesthetic solutions. In the U.S., outpatient surgeries accounted for over 60% of all surgical procedures in 2023, creating a surge in demand for inhalation anesthetics.

Rising Investments in Healthcare Infrastructure

: Emerging markets, particularly in Asia-Pacific, are investing heavily in healthcare infrastructure. China alone has invested over $70 billion in healthcare expansion in 2023, boosting the demand for modern anesthetic equipment and solutions like inhalation anesthesia.

Key Challenges:

High Cost of Inhalation Anesthetic Agents

: The cost of modern anesthetic agents, such as sevoflurane and desflurane, can be prohibitive for healthcare providers, particularly in low- and middle-income countries, limiting their adoption.

Environmental Concerns

: Inhalation anesthetics are known to have a high global warming potential (GWP), contributing to climate change. The environmental impact of these agents is becoming a growing concern, prompting the healthcare industry to seek more sustainable alternatives.

Risk of Post-Operative Complications

: Although modern agents are generally safe, some patients still experience post-operative side effects such as nausea, vomiting, and respiratory issues. This can deter healthcare providers from using inhalation anesthetics in certain cases.

Strict Regulatory Requirements

: The development and approval of new anesthetic agents face stringent regulations across different countries, slowing the market's growth and increasing the cost and time associated with bringing new products to market.

Key Trends:

Shift Towards Short-Acting Anesthetics

: There is an increasing preference for short-acting inhalation anesthetics such as sevoflurane and desflurane, which offer faster recovery times and reduced post-operative complications, enhancing patient throughput and surgical efficiency.

Technological Advancements in Delivery Systems

: Innovations in anesthesia delivery systems, including advanced vaporizer technologies and automated anesthesia workstations, are improving the precision and safety of inhalation anesthesia, leading to more effective and controlled administration.

Growth of Ambulatory and Outpatient Surgeries

: The rising trend of ambulatory and outpatient surgeries is driving the demand for inhalation anesthetics that facilitate quick recovery and minimal side effects, supporting the increased volume of same-day surgical procedures.

Emergence of Eco-Friendly Anesthetic Agents

: There is a growing focus on developing environmentally friendly inhalation anesthetics with lower global warming potential (GWP) and reduced environmental impact, driven by increasing awareness of sustainability and regulatory pressures.

Global Inhalation Anesthesia Market Regional Analysis

Here is a more detailed regional analysis of the global inhalation anesthesia market:

North America:

North America is the dominant region in the inhalation anesthesia market, driven by the high volume of surgical procedures and advanced healthcare infrastructure. The United States, in particular, leads in both market size and technological advancements. According to the Centers for Disease Control and Prevention (CDC), there are approximately 50 million surgical procedures performed annually in the U.S., creating a substantial demand for inhalation anesthesia. The region's focus on innovation and safety is supported by significant investments in research and development, contributing to its leading position in the global market.

In addition, North America benefits from a well-established network of healthcare facilities and high adoption rates of advanced anesthetic technologies. The U.S. and Canada are investing heavily in upgrading medical infrastructure, with the U.S. allocating over $20 billion for healthcare improvements in 2023 alone. This investment is enhancing the availability and quality of inhalation anesthesia, ensuring that North America remains at the forefront of the market.

Asia Pacific:

Asia Pacific is the fastest-growing region in the inhalation anesthesia market, fueled by rapid healthcare advancements and expanding medical infrastructure. Countries such as China and India are experiencing significant growth due to their large population bases and increasing healthcare investments. In 2023, China's healthcare sector received over $70 billion in investments, supporting the adoption of advanced anesthesia technologies. The rising number of surgeries and the push for modern healthcare facilities are driving the demand for inhalation anesthetics in the region.

Additionally, the expanding trend of medical tourism and the increasing focus on improving healthcare access in developing countries contribute to the growth of the inhalation anesthesia market in Asia Pacific. The region is seeing rapid advancements in both public and private healthcare sectors, enhancing the availability and use of modern anesthetic solutions.

Global Inhalation Anesthesia Market: Segmentation Analysis

The Global Inhalation Anesthesia Market is segmented on the basis of Product, End User, Application, and Geography.

Inhalation Anesthesia Market, By Product

• Desflurane
• Isoflurane
• Sevoflurane

Based on Product, the Global Inhalation Anesthesia Market is segmented into Desflurane, Isoflurane, Sevoflurane. Sevoflurane is the dominant segment due to its favorable properties, including rapid onset, quick recovery, and minimal side effects, making it the preferred choice for various surgical procedures. Sevoflurane's ease of use and efficiency have established it as the leading anesthetic agent. Desflurane is the fastest-growing segment, driven by its ultra-fast onset and recovery times, which are increasingly sought after for outpatient and short-duration surgeries. The demand for desflurane is rising as healthcare providers aim for improved patient turnover and minimized anesthesia-related complications.

Inhalation Anesthesia Market, By End User

• Hospital
• Ambulatory Surgical Centers

Based on End User, the Global Inhalation Anesthesia Market is segmented into Hospital, Ambulatory Surgical Centers. Hospitals are the dominant segment due to their large volume of surgical procedures and advanced infrastructure, which necessitates the use of various anesthetic agents. However, Ambulatory surgical centers (ASCs) are the fastest-growing segment, driven by the increasing trend towards outpatient surgeries and minimally invasive procedures. ASCs are adopting inhalation anesthesia more rapidly due to its benefits in quick recovery and efficient patient throughput, reflecting a shift towards more cost-effective and patient-friendly surgical environments.

Inhalation Anesthesia Market, By Application

• Maintenance
• Induction

Based on Application, the Global Inhalation Anesthesia Market is segmented into Maintenance, Induction. Maintenance anesthesia is the dominant segment due to its critical role in sustaining anesthesia throughout lengthy surgical procedures, ensuring patient stability and comfort. Conversely, Induction anesthesia is the fastest-growing segment, driven by advancements in rapid-acting anesthetic agents that facilitate quicker onset and smoother transitions into the anesthetic state. The increasing preference for efficient and effective induction methods is reflecting the broader trend towards optimizing surgical workflows and enhancing patient experiences.

Inhalation Anesthesia Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on the Geography, the Global Inhalation Anesthesia Market are classified into North America, Europe, Asia Pacific, and Rest of World. North America is the dominant region in the inhalation anesthesia market, driven by the high volume of surgical procedures and advanced healthcare infrastructure. The United States, in particular, leads in both market size and technological advancements. Asia Pacific is the fastest-growing region in the inhalation anesthesia market, fueled by rapid healthcare advancements and expanding medical infrastructure. Countries such as China and India are experiencing significant growth due to their large population bases and increasing healthcare investments.

Key Players

• The "Global Inhalation Anesthesia Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market
• AbbVie Inc., Baxter International Inc., Dechra Pharmaceuticals PLC, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd, Lunan Pharmaceutical Group Co. Ltd.
• Our
• market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
• Global Inhalation Anesthesia Market: Recent Developments
• In August 2024 Baxter International announced FDA approval for its latest anesthesia delivery system, designed to improve precision and safety in administering inhalation anesthesia. The system incorporates advanced monitoring features to enhance patient care during surgeries.
• In July 2024 the European Medicines Agency approved Halofane, a new inhalation anesthetic agent by Halothane Pharma, noted for its reduced side effects and faster recovery times. This approval opens new markets across Europe and strengthens the company's product portfolio.
• In June 2024 Drager launched a state-of-the-art vaporizer for inhalation anesthesia that offers precise dose adjustments and improved patient safety. This technology is expected to streamline anesthesia management and enhance surgical outcomes in hospitals globally.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL INHALATION ANESTHESIA MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL INHALATION ANESTHESIA MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL INHALATION ANESTHESIA MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Desflurane
• 5.3 Isoflurane
• 5.4 Sevoflurane

6 GLOBAL INHALATION ANESTHESIA MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Maintenance
• 6.3 Induction

7 GLOBAL INHALATION ANESTHESIA MARKET, BY END-USER

• 7.1 Overview
• 7.2 Hospital
• 7.3 Ambulatory Surgical Centers

8 GLOBAL INHALATION ANESTHESIA MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East And Africa

9 GLOBAL INHALATION ANESTHESIA MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 AbbVie Inc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Baxter International Inc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Dechra Pharmaceuticals PLC
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Fresenius Kabi AG
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Hikma Pharmaceuticals PLC
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Jiangsu Hengrui Medicine Co. Ltd
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Lunan Pharmaceutical Group Co. Ltd
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Merck KGaA
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.7 Piramal Enterprises Limited
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Troikaa Pharmaceuticals Ltd
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research